The Microbiota in Kidney Donation and Transplantation

Longitudinal Characterisation of the Host Microbiota After Kidney Donation and Transplantation

The human gastrointestinal tract harbours ~40 trillion microbial cells, far outnumbering the cell number, and therefore the genetic content of its host. How this genetically diverse bacterial (collectively referred as 'microbiota') co-resident modulates host homeostasis is largely unknown. We are increasing gaining a better understanding how the microbes modulate mucosal and systemic metabolic/immune and organ systems including the kidney, heart and the brain. Therapeutic targeting of the gastrointestinal (GI) microbiota may help improve clinical outcomes in conditions as diverse as arthritis, cardiovascular disease, and cancer. In contrast to other organ systems, studies investigating the role of the microbiota in modulating clinical outcomes in renal transplantation lags behind.

The aim of the study is to examine (a) how alterations in the urinary and GI microbiota and associated metabolites impact on host immunity after renal transplantation, and (b) whether such changes are correlated with post-transplant complications, such as rejection, development of de novo donor specific antibodies, metabolic complications (e.g post-transplant diabetes) and infections. Participants will be followed before and up to twelve months post-transplantation, and, longitudinal microbial data will be correlated with in-depth immune phenotyping and clinical end-points to define the impact that changes in urinary and GI microbial ecology have on kidney transplant outcomes.

Study Overview

• Status: Recruiting
• Conditions: Kidney Diseases; Urinary Tract Infections; Kidney Transplant Failure and Rejection
• Intervention / Treatment: Other: Pre-operative assessment - blood, urine, & faecal sample; Other: Post-operative day 3 assessment - blood, urine, & faecal sample; Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample; Other: Post-operative 3 month assessment - blood, urine, & faecal sample; Other: Pre-operative 6 month assessment - blood, urine, & faecal sample; Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample

• Study Type: Observational
• Enrollment (Estimated): 130

Contacts and Locations

• Study Contact: Name: Reza Motallebzadeh; Phone Number: 020 7794 0500; Email: r.motallebzadeh@ucl.ac.uk

Study Locations

• United Kingdom
  • London, United Kingdom, NW3 2QG
    • Recruiting
    • Royal Free London NHS Trust
    • Contact: Reza Motallebzadeh, PhD FRCS; Email: r.motallebzadeh@ucl.ac.uk
    • Contact: Amanda Bidle; Phone Number: 32535 00442077940500; Email: rf.sponsoredresearch@nhs.net
    • Principal Investigator: Alan Salama, PhD FRCP
    • Principal Investigator: Mark Harber, FRCP
    • Principal Investigator: Anne Pesenacker, PhD
    • Principal Investigator: Mona Bajaj-Elliott, PhD
    • Principal Investigator: Jennifer Rohn, PhD
    • Principal Investigator: Maria De Iorio, PhD
    • Principal Investigator: Kevin Bryson, PhD
    • Sub-Investigator: Gurpeet Badhan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Renal transplant live-donors and recipients of live-donor and cadaveric renal transplants

Description

Inclusion Criteria:

• All adult (≥18 years old) undergoing living donor nephrectomy or kidney transplantation. Patients willing to provide samples including Urine, Blood, Faecal samples.

  1. Participant able to give Informed Consent
  2. All patients will be at least 18 years old
  3. Patients will either be a live renal transplant donor or a renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible renal transplant.
  4. Patients attending hospital clinics at participating centre for routine clinical follow -up.
  5. Patients willing to comply with study procedures and willing to provide blood, faecal and urine samples.

Exclusion Criteria:

1. Patients under the age of 18 years
2. Patients unable to give informed consent
3. Patients not able to comply with study procedures or follow-up visits
4. Patients that are not a live renal donor or that are not on the waiting list to have or have not had an ABO blood group compatible renal transplant and are not attending hospital outpatient clinics at participating study centres for routine clinical follow-up.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Kidney transplant live-donor; Participants that will be a planned live renal transplant donor	Other: Pre-operative assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing; Other: Post-operative day 3 assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.; Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.; Other: Post-operative 3 month assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.; Other: Pre-operative 6 month assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.; Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.
Kidney transplant recipient; Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant	Other: Pre-operative assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing; Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.; Other: Post-operative 3 month assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.; Other: Pre-operative 6 month assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.; Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample; Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in gastrointestinal and urinary microbiota composition and diversity	To understand the overall impact of transplantation on changes to the urinary and GI microbiota, the relative abundance of bacterial taxa will be evaluated using 16S rRNA gene sequencing methodologies. Alpha and Beta diversity indices will be determined from urine samples and faecal samples before and after live-donation and transplantation.	1 year
Correlation of change in gastrointestinal and urinary microbiota diversity with post-transplantation outcomes.	Incidence of renal graft dysfunction will be determined by the Modification of Diet in Renal Disease (MDRD)-derived estimated Glomerular Filtration Rate (eGFR) at 12 months. Graft survival time - date of transplantation to date of irreversible graft failure signified by return to dialysis (or re-transplantation, whichever is earlier) or the date of last follow-up during the period when the transplant was still functioning. In the event of death with a functioning graft, the follow-up period will be censored at the date of death.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in frequency of conventional and regulatory immune phenotypes and correlation with clinical outcome and microbial diversity changes	A panel of validated immune monitoring assays (including multi-colour flow cytometry, intracellular cytokine staining, enzyme-linked immune absorbent spot [ELISpot], enzyme-linked immunosorbent assay [ELISA] and transcriptional analysis) will be used to analyse immunological parameters in patient samples.	1 year
Change in microbial-associated metabolite profile and correlation with clinical outcomes and/or microbial diversity changes	A combination of 1H nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry will be used to measure the metabolic phenotype of urine and faecal samples from transplant donors and recipients (pre-operatively and up to 12 months after surgery).	1 year
Incidence of renal graft dysfunction as determined by the MDRD-derived estimated Glomerular Filtration Rate (eGFR).	A significant deterioration in graft dysfunction is defined as the percent of patients exhibiting an eGFR <45 mL/min/1.73m2 at month 12 or a decrease in eGFR ≥10 mL/min/1.73m2 from month 3 to month 12 after transplantation.	1 year
The proportion of patients reaching a defined CKD stage at up to 5 years after transplantation.	Defined by the kidney disease outcomes quality initiative for CKD stages, with eGFR <30 mL/min/1.73m2 considered to be advanced renal dysfunction.	5 years
Incidence of biopsy proven acute or chronic cellular or humoral rejection up to 5 years after transplantation as per Banff classification	Revised Banff 2017 classification of antibody-mediated rejection and T cell-mediated rejection in renal allografts.	5 years
Incidence of post-donation and post-transplant bacterial or viral infections up to 5 years after surgery	Infectious complications will include, but not be limited to, urinary tract infections (defined as a positive urine culture [>50,000 CFUs/ml] from mid-stream urine, and categorised as asymptomatic bacteriuria [no symptoms], cystitis [lower urinary tract symptoms without systemic features] or pyelonephritis [systemic features, graft dysfunction, CRP>50]), BK viraemia, cytomegalovirus (CMV) viraemia, and respiratory tract (RV) infections.	5 years
Patient and graft survival rates up to 5 years after transplantation.	Graft survival time will be calculated from the date of transplantation to the date of irreversible graft failure signified by return to dialysis (or re-transplantation, whichever is earlier) or the date of last follow-up during the period when the transplant was still functioning. In the event of death with a functioning graft, the follow-up period will be censored at the date of death.	5 years

Collaborators and Investigators

• Sponsor: Royal Free Hospital NHS Foundation Trust
• Collaborators: University College, London
• Investigators: Study Chair: Research and Development Manager, Sponsor GmbH

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2020
• Primary Completion (Estimated): June 1, 2025
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: May 12, 2020
• First Submitted That Met QC Criteria: May 12, 2020
• First Posted (Actual): May 14, 2020

Study Record Updates

• Last Update Posted (Estimated): December 14, 2023
• Last Update Submitted That Met QC Criteria: December 13, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Urinary Tract Infections
• Other Study ID Numbers: 125570

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No